The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Pros and cons of phage therapy
Open accessAbstract
Many publications list advantages and disadvantages associated with phage therapy, which is the use of bacterial viruses to combat populations of nuisance or pathogenic bacteria. The goal of this commentary is to discuss many of those issues in a single location. In terms of "Pros," for example, phages can be bactericidal, can increase in number over the course of treatment, tend to only minimally disrupt normal flora, are equally effective against antibiotic-sensitive and antibiotic-resistant bacteria, often are easily discovered, seem to be capable of disrupting bacterial biofilms, and can have low inherent toxicities. In addition to these assets, we consider aspects of phage therapy that can contribute to its safety, economics, or convenience, but in ways that are perhaps less essential to the phage potential to combat bacteria. For example, autonomous phage transfer between animals during veterinary application could provide convenience or economic advantages by decreasing the need for repeated phage application, but is not necessarily crucial to therapeutic success. We also consider possible disadvantages to phage use as antibacterial agents. These "Cons," however, tend to be relatively minor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Self-citationPhage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Self-citationMerabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004944 · Cited by 511
Bacteriophages as potential new therapeutics to replace or supplement antibiotics
Kutateladze, M., & Adamia, R. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.08.001 · Cited by 483
Summers, W. C. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.437 · Cited by 474
Effect of antibiotics in the environment on microbial populations
Ding, C., & He, J. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2649-5 · Cited by 465
Phage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
Phage therapy: past history and future prospects.
Carlton, R. M. (1999) · PubMed · Cited by 342
Bacteriophages show promise as antimicrobial agents
Alisky, J., Iczkowski, K., Rapoport, A., & Troitsky, N. (1998) · Journal of Infection · doi:10.1016/s0163-4453(98)92874-2 · Cited by 318
Phage therapy: Facts and fiction
Skurnik, M., & Strauch, E. (2006) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2005.09.002 · Cited by 296
Abedon, S., & Thomas-Abedon, C. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725410 · Cited by 284
Self-citationBacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential
Barrow, P. A., & Soothill, J. S. (1997) · Trends in Microbiology · doi:10.1016/s0966-842x(97)01054-8 · Cited by 280
Biotechnological challenges of phage therapy
Skurnik, M., Pajunen, M., & Kiljunen, S. (2007) · Biotechnology Letters · doi:10.1007/s10529-007-9346-1 · Cited by 203
Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance
Stratton, C. W. (2003) · Emerging infectious diseases · doi:10.3201/eid0901.020172 · Cited by 159
Goodridge, L. D. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725348 · Cited by 155
Bacteriophage Therapy ofSalmonella enterica:A Fresh Appraisal of Bacteriophage Therapy
Capparelli, R., Nocerino, N., Iannaccone, M., Ercolini, D., Parlato, M., Medaglia, C., & Iannelli, D. (2009) · The Journal of Infectious Diseases · doi:10.1086/648478 · Cited by 120
Phage Therapy in Animals and Agribusiness
Sulakvelidze, A., & Barrow, P. (2004) · CRC Press eBooks · doi:10.1201/9780203491751.ch13 · Cited by 99
Gupta, R., & Prasad, Y. (2010) · Current Microbiology · doi:10.1007/s00284-010-9699-x · Cited by 88
The potential of phages to prevent MRSA infections
Mann, N. H. (2008) · Research in Microbiology · doi:10.1016/j.resmic.2008.04.003 · Cited by 81
What Is an Antibiotic? Revisited
Bentley, R., & Bennett, J. W. (2003) · Advances in applied microbiology · doi:10.1016/s0065-2164(03)01012-8 · Cited by 34
Cited by
Phage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Self-citationAntibiotic resistance and persistence—implications for human health and treatment perspectives
Huemer, M., Mairpady Shambat, S., Brugger, S. D., & Zinkernagel, A. S. (2020) · The EMBO Reports · doi:10.15252/embr.202051034 · Cited by 850
Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System
Van Belleghem, J. D., Dąbrowska, K., Vaneechoutte, M., Barr, J. J., & Bollyky, P. L. (2018) · Viruses · doi:10.3390/v11010010 · Cited by 408
More Is Better: Selecting for Broad Host Range Bacteriophages
Ross, A., Ward, S., & Hyman, P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01352 · Cited by 367
Revisiting phage therapy: new applications for old resources
Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.01.006 · Cited by 310
Metadata
- Authors
- Loc-Carrillo, C., & Abedon, S. T.
- Venue
- Bacteriophage
- Publisher
- Informa UK Limited
- Published
- 2011-03
- Volume
- 1
- Issue
- 2
- Pages
- 111-114
- ISSN
- 2159-7073 (ISSN-L)
- 2159-7081
- OpenAlex
- W2090817404
- Cited by
- 1,020
- References
- 21
- FWCI
- 16.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.